HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV vectored immunotherapy in humanized mice
N. M. S. Galvez, A. D. Nitido, S. B. Yoo, Y. Cao, C. E. Deal, C. L. Boutros, S. W. MacDonald, Y. E. Soto Albrecht, E. C. Lam, M. L. Sheehan, D. Parsons, A. Z. Lin, M. J. Deymier, J. M. Brady, B. Moon, , A. B. Balazs
This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.
bioRxiv · Jul 11, 2024Microbiology